REGN Regeneron Pharmaceuticals, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

REGN [NASD]

Regeneron Pharmaceuticals, Inc.

Healthcare | Biotechnology | USA

statements

Index	S&P 500	P/E	21.67	EPS (ttm)	25.83	Insider Own	0.90%	Shs Outstand	109.60M	Perf Week	-0.96%
Market Cap	57.84B	Forward P/E	16.52	EPS next Y	33.88	Insider Trans	-45.37%	Shs Float	101.66M	Perf Month	-9.70%
Income	2.98B	PEG	1.78	EPS next Q	7.12	Inst Own	90.00%	Short Float	1.57%	Perf Quarter	-8.11%
Sales	8.00B	P/S	7.23	EPS this Y	-10.80%	Inst Trans	22.01%	Short Ratio	2.23	Perf Half Y	12.71%
Book/sh	82.64	P/B	6.77	EPS next Y	17.65%	ROA	20.30%	Target Price	674.63	Perf Year	102.47%
Cash/sh	30.43	P/C	18.39	EPS next 5Y	12.18%	ROE	27.90%	52W Range	272.02 - 664.64	Perf YTD	49.08%
Dividend	-	P/FCF	23.85	EPS past 5Y	44.00%	ROI	16.10%	52W High	-15.78%	Beta	0.52
Dividend %	-	Quick Ratio	1.80	Sales past 5Y	22.80%	Gross Margin	88.20%	52W Low	105.79%	ATR	19.11
Employees	8100	Current Ratio	2.10	Sales Q/Q	23.70%	Oper. Margin	34.60%	RSI (14)	42.16	Volatility	3.41% 3.48%
Optionable	Yes	Debt/Eq	0.24	EPS Q/Q	351.70%	Profit Margin	37.30%	Rel Volume	3.01	Prev Close	573.61
Shortable	Yes	LT Debt/Eq	0.08	Earnings	Aug 05 BMO	Payout	0.00%	Avg Volume	717.13K	Price	559.78
Recom	2.10	SMA20	-1.72%	SMA50	-6.76%	SMA200	7.58%	Volume	2,154,992	Change	-2.41%

Aug-20-20

Downgrade

The Benchmark Company

Buy → Hold

Jul-09-20

Upgrade

SunTrust

Hold → Buy

$400 → $750

May-26-20

Upgrade

Wells Fargo

Equal Weight → Overweight

$559 → $734

Apr-28-20

Downgrade

Citigroup

Buy → Neutral

$540 → $575

Apr-17-20

Upgrade

The Benchmark Company

Hold → Buy

$655

Apr-08-20

Initiated

The Benchmark Company

Hold

Mar-31-20

Initiated

Wolfe Research

Peer Perform

Feb-27-20

Initiated

Barclays

Overweight

$530

Feb-26-20

Upgrade

Canaccord Genuity

Hold → Buy

$550

Feb-26-20

Downgrade

Robert W. Baird

Outperform → Neutral

$410

Feb-25-20

Upgrade

Jefferies

Hold → Buy

$355 → $492

Feb-11-20

Upgrade

Argus

Hold → Buy

$430

Dec-24-19

Initiated

Raymond James

Mkt Perform

Dec-16-19

Downgrade

Evercore ISI

Outperform → In-line

Dec-13-19

Upgrade

Credit Suisse

Neutral → Outperform

$400

Nov-12-19

Initiated

SunTrust

Hold

$360

Nov-07-19

Upgrade

Citigroup

Neutral → Buy

$340 → $420

Oct-17-19

Resumed

BofA/Merrill

Neutral

$325

Sep-23-19

Upgrade

Guggenheim

Neutral → Buy

$355 → $403

Aug-07-19

Upgrade

Robert W. Baird

Neutral → Outperform

$410

Sep-30-20 05:12PM	U.S. Cases Rise 0.6%; N.J. Positivity Rate Rises: Virus Update Bloomberg
04:16PM	Covid Report: Regeneron, Moderna, CureVac Up As Possible Coronavirus Cures Advance Investor's Business Daily
03:56PM	2 Regeneron Analysts On COVID-19 Antibody Cocktail's Emergency Use Authorization Prospects Benzinga
03:55PM	Regeneron Reports Positive Results From COVID-19 Treatment Clinical Trial Motley Fool
03:47PM	Coronavirus Latest: Wednesday, September 30 Yahoo Finance Video
01:10PM	Coronavirus update: Regeneron antibody therapy shows promise as feared 2nd wave swells Yahoo Finance
12:20PM	Dow Jones Surges 450 Points To Retake Key Support; Stocks Rally After Fiery Debate Investor's Business Daily
12:04PM	Dow Jones Jumps 450 Points On Jobs Data, Coronavirus Stimulus Hopes; Apple, Tesla Advance Investor's Business Daily
10:51AM	Quarter Ends With Focus On Regeneron's Virus Cocktail, Disney Layoffs, Micron Results Benzinga
10:25AM	Looking Into Regeneron Pharmaceuticals's Return On Capital Employed Benzinga
10:03AM	Dow Jones Today, Stocks Rise To Put The Wraps On A Powerful Q3; Disney Dives On Covid Ruling Investor's Business Daily
09:13AM	Regenerons Good News on Covid Antibodies Is Positive for Vaccines, Too Barrons.com
09:13AM	Moderna and Regeneron Gain on Positive Covid-19 Vaccine Trial Results TheStreet.com
08:30AM	The Dow Is Dropping, Disney Stock Is Slipping, and Regeneron Is Jumping Barrons.com
07:51AM	Regeneron Up 4% As Covid-19 Cocktail Lowers Viral Levels; Analyst Says Hold SmarterAnalyst
07:24AM	Debate Spin, Slowing Recovery, Stimulus Hope, Notes on Regeneron, Disney, Tesla TheStreet.com
Sep-29-20 10:12PM	Regeneron says its COVID-19 treatment reduces viral levels, improves symptoms Reuters
10:01PM	Regeneron Says COVID-19 Antibody Cocktail Helped Non-Hospitalized Patients Heal Faster In Early Trials Benzinga
06:08PM	Regeneron Says Antibodies Helped Covid Patients Recover Faster. Here Are the Next Steps. Barrons.com
05:42PM	Regeneron Posts Positive Initial Data On Its Covid-19 Treatment Investor's Business Daily
04:19PM	Regeneron says that trial coronavirus drug cocktail cut virus load, aided patient recovery MarketWatch
04:01PM	Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients PR Newswire
04:01PM	Regeneron says its COVID-19 treatment reduces viral levels, improves symptoms Reuters
12:41PM	Scott+Scott Attorneys at Law LLP Continues Investigating Regeneron Pharmaceuticals, Inc.'s Directors and Officers for Breach of Fiduciary Duty - REGN PR Newswire
Sep-23-20 06:12AM	3 Safe Coronavirus Stocks to Buy Ahead of a Market Crash Motley Fool
Sep-22-20 04:07PM	Mercks Lung Cancer Drug Is a Blockbuster. Other Companies Are Starting to Challenge Its Dominance. Barrons.com
Sep-21-20 08:25AM	Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of 50% PR Newswire
03:05AM	Sanofi, Regenerons Libtayo Delivers Positive Results In Pivotal Lung Cancer Trial SmarterAnalyst
Sep-18-20 01:13PM	Sorrento Gets FDA Nod for Phase I Study on Coronavirus Antibody Zacks
09:03AM	Roche Reports Phase 3 Progress for Its Covid Pneumonia Treatment TheStreet.com
03:05AM	Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy in Locally Advanced Basal Cell Carcinoma Featured as a Late-breaking Presentation at ESMO PR Newswire
Sep-17-20 04:31PM	Eli Lilly, Amgen Teaming Up On Covid-19 Treatments Investor's Business Daily
Sep-16-20 01:57PM	Lilly and Pfizer Are Testing Treatments for Hospitalized Covid Patients Barrons.com
12:57PM	Coronavirus update: Operation Warp Speed readies for vaccine as CDC tries to manage expectations Yahoo Finance
09:47AM	Biotech Stock Roundup: GILD to Buy IMMU, SGEN Collaborates With Merck & More Zacks
07:33AM	2 COVID-19 Antibody Stocks to Buy Right Now Motley Fool
Sep-15-20 03:41PM	Top Biotech Stocks for Q4 2020 Investopedia
10:15AM	S&P 500 Buybacks Decline 55.4% to $88.7 Billion; Significant Reductions Expected to continue in Q3 2020 PR Newswire
10:06AM	Regeneron's Cocktail for Coronavirus Selected for RECOVERY Study Zacks
06:45AM	Could This COVID-19 Drug Developer's Stock Make You Filthy Rich? Motley Fool
Sep-14-20 03:42PM	A Look At The Fair Value Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Simply Wall St.
11:30AM	Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year? Zacks
09:30AM	Imanis Life Sciences to Present IMMUNO-COV, a First-in-Class Neutralizing Antibody Test for COVID-19, at American Society of Gene and Cell Therapy Symposium GlobeNewswire
07:00AM	Regeneron's antibody drug added to UK Recovery trial of COVID treatments Reuters
07:00AM	RECOVERY COVID-19 Phase 3 Trial to Evaluate Regeneron's REGN-COV2 Investigational Antibody Cocktail in the UK PR Newswire
12:59AM	FDA Grants Dupixent® (dupilumab) Breakthrough Therapy Designation for Eosinophilic Esophagitis PR Newswire
Sep-11-20 10:00AM	Its Likely Too Late for Regenerons Virus Treatment Barrons.com
Sep-09-20 10:52AM	Regeneron expects to report biomarker data for COVID-19 therapy by September end Reuters
Sep-08-20 10:02AM	CKPT: Checkpoints Got Skin in the Game: Interim Results Next Week Zacks Small Cap Research
05:20AM	S.Korea's Celltrion to begin commercial production of COVID-19 antibody drug Reuters
04:59AM	Regeneron, Sanofis Dupixent Shows Sustained Asthma Benefits In 3-Yr Trial SmarterAnalyst
04:34AM	BiohavenPharmaHldg Reaches 80-Plus Relative Strength Rating Benchmark Investor's Business Daily
12:59AM	Dupixent® (dupilumab) Long-term Data Show Sustained Improvement in Lung Function and Reduction in Severe Exacerbations in Adults and Adolescents with Moderate-to-severe Asthma PR Newswire
Sep-05-20 08:30AM	Kaskela Law LLC Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Long-Term REGN Stockholders to Contact the Firm PR Newswire
Sep-04-20 11:31AM	Regeneron (REGN) Down 7.1% Since Last Earnings Report: Can It Rebound? Zacks
Sep-03-20 10:56AM	Merck CEO sees human trials for COVID-19 vaccine candidate 'fairly soon' Reuters -5.37%
07:00AM	Late-breaking Libtayo® (cemiplimab) pivotal data in advanced non-small cell lung cancer and basal cell carcinoma to be presented at ESMO PR Newswire
Sep-01-20 10:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals Inc. ACCESSWIRE
04:10PM	Covid Roundup: AstraZeneca U.S. Phase 3 Vaccine Trials Start; Sanofi Drug Fails Test Investor's Business Daily
02:07PM	Kevzara Fails COVID-19 Patients for the Last Time Motley Fool
09:09AM	Sanofi and Regeneron Give Up On Arthritis Drug to Treat Covid-19. Why Thats OK. Barrons.com
08:39AM	Sanofi, Regeneron: Kevzara fails in late-stage COVID-19 trial MarketWatch
08:32AM	The Daily Biotech Pulse: Sanofi, Regeneron Drop COVID-19 Study, 2 Positive AstraZeneca Catalysts, Brickell Awarded Japanese Patent Benzinga
04:03AM	Sanofi, Regeneron Rheumatoid Arthritis Drug Proves Ineffective Against COVID-19 Benzinga
03:02AM	Sanofi Halts Kevzara Tests for Covid as Drug Fails to Help Bloomberg
01:52AM	Sanofi says Kevzara drug fails as possible COVID-19 treatment Reuters
01:17AM	Sanofi says Kevzara drug fails as possible COVID-19 treatment Reuters
Aug-31-20 11:25PM	Hedge Funds Never Been More Bullish On Regeneron Pharmaceuticals Inc (REGN) Insider Monkey
08:54PM	REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm GlobeNewswire
08:00AM	GSK, partner Vir join race to find COVID-19 antibody treatment Reuters
Aug-29-20 10:12PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals Inc. GlobeNewswire
Aug-28-20 04:29PM	Horizon Therapeutics, IBD Stock Of The Day, Rides Rare-Disease Drug To Buy Points Investor's Business Daily
Aug-27-20 11:30AM	Has Regeneron Pharmaceuticals (REGN) Outpaced Other Medical Stocks This Year? Zacks
07:24AM	These 5 Stocks Are The Biggest S&P 500 Healthcare Winners of 2020 Motley Fool
Aug-26-20 03:28PM	Top Stocks for September 2020 Investopedia
07:26AM	Better Buy: CVS vs. Regeneron Motley Fool
07:00AM	Regeneron Announces Investor Conference Presentations PR Newswire
06:06AM	3 Healthcare Stocks Billionaires Wouldn't Stop Buying in Q2 Motley Fool
Aug-25-20 06:18PM	AstraZeneca Starts Clinical Trial Testing Its COVID-19 Treatment Antibody Cocktail Motley Fool
04:35PM	AstraZeneca Coronavirus Treatment Testing Begins, Called 'Important Milestone' Investor's Business Daily
02:09PM	Coronavirus update: FDA defends plasma authorization as antibody treatment options expand Yahoo Finance
Aug-24-20 01:30PM	Trump Announces Authorization of Blood Plasma Covid Treatment. The Only Hitch: It Might Not Work. Barrons.com
01:12PM	Top Health Care Stocks for September 2020 Investopedia
08:30AM	Pharma Rivals Are Fighting Covid Together. Why Stop There? Bloomberg
Aug-22-20 09:18PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals Inc. GlobeNewswire
Aug-21-20 09:24AM	Regeneron Gains on Coronavirus Treatment Development Efforts Zacks
Aug-20-20 12:37PM	SHAREHOLDER ALERT: Lowey Dannenberg Is Investigating Regeneron Pharmaceuticals, Inc. (REGN) for Potential Breaches of Fiduciary Duty by Its Board of Directors GlobeNewswire
09:37AM	Regenerons Covid-19 Antibody Isnt a Slam Dunk for Profit, Analyst Says Barrons.com
08:05AM	Airbnb Picked a Terrible Time to File for an IPO Barrons.com
06:08AM	3 Biotech Stocks You Can Buy and Hold for the Next Decade Motley Fool
Aug-19-20 10:09PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals Inc. PR Newswire
06:24PM	President Trump Says U.S. Will Demand That the United Nations Restores Iran Sanctions Barrons.com
05:02PM	Regeneron and Roche Team Up to Triple Production of COVID-19 Treatment Motley Fool
05:01PM	New England Journal of Medicine Publishes Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol PR Newswire
03:33PM	Coronavirus Latest: Wednesday, August 19 Yahoo Finance Video
11:42AM	Regenerons Deal With Roche to Make Covid Antibody Should Add Credibility to This Program Barrons.com
11:33AM	Regeneron, Roche to Distribute Antibody Cocktail for Coronavirus Zacks
10:20AM	Biotech Stock Roundup: GILD Gets CRL, REGN Collaborates With RHHBY & More Zacks
10:17AM	Regeneron Partners With Roche to Make Covid-19 Drug TheStreet.com
07:55AM	Target, Lowe's, Nvidia and Joe Biden - 5 Things You Must Know Wednesday TheStreet.com

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BROWN MICHAEL S	Director	Sep 22	Option Exercise	378.77	5,090	1,927,917	5,733	Sep 23 04:01 PM
BROWN MICHAEL S	Director	Sep 22	Sale	552.36	1,000	552,360	9,349	Sep 23 04:01 PM
BROWN MICHAEL S	Director	Sep 22	Sale	552.36	5,090	2,811,512	643	Sep 23 04:01 PM
GOLDSTEIN JOSEPH L	Director	Sep 22	Sale	552.36	20	11,047	5,643	Sep 23 04:00 PM
GOLDSTEIN JOSEPH L	Director	Sep 21	Option Exercise	376.76	16,574	6,244,372	22,217	Sep 23 04:00 PM
GOLDSTEIN JOSEPH L	Director	Sep 21	Sale	549.86	16,554	9,102,446	5,663	Sep 23 04:00 PM
RYAN ARTHUR F	Director	Sep 01	Sale	604.58	100	60,458	28,443	Sep 03 04:18 PM
SING GEORGE L	Director	Aug 31	Sale	612.06	10,000	6,120,555	54,415	Aug 31 04:36 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Aug 31	Sale	615.04	4,672	2,873,467	14,438	Aug 31 04:37 PM
POON CHRISTINE A	Director	Aug 28	Option Exercise	28.44	40,000	1,137,550	41,433	Aug 31 04:35 PM
POON CHRISTINE A	Director	Aug 28	Sale	601.22	40,000	24,048,715	1,433	Aug 31 04:35 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Aug 27	Option Exercise	52.03	10,000	520,300	21,241	Aug 31 04:37 PM
SING GEORGE L	Director	Aug 25	Option Exercise	273.67	12,750	3,489,293	97,165	Aug 27 04:23 PM
Van Plew Daniel P	EVP & General Mgr Industrial O	Aug 25	Sale	610.89	27,109	16,560,738	20,001	Aug 27 04:21 PM
SING GEORGE L	Director	Aug 25	Sale	612.00	1,000	612,000	3,700	Aug 27 04:23 PM
SING GEORGE L	Director	Aug 25	Sale	607.28	32,750	19,888,518	64,415	Aug 27 04:23 PM
SING GEORGE L	Director	Aug 24	Option Exercise	177.82	10,037	1,784,779	104,452	Aug 24 06:13 PM
SING GEORGE L	Director	Aug 24	Sale	593.63	20,037	11,894,577	84,415	Aug 24 06:13 PM
SING GEORGE L	Director	Aug 21	Option Exercise	117.24	9,963	1,168,071	114,078	Aug 24 06:13 PM
SING GEORGE L	Director	Aug 21	Sale	605.12	19,963	12,080,040	94,415	Aug 24 06:13 PM
GOLDSTEIN JOSEPH L	Director	Aug 21	Sale	617.18	1,000	617,180	5,643	Aug 24 05:19 PM
Van Plew Daniel P	EVP & General Mgr Industrial O	Aug 20	Option Exercise	179.13	75,000	13,434,750	95,001	Aug 24 04:47 PM
SING GEORGE L	Director	Aug 20	Option Exercise	57.11	10,000	571,100	114,415	Aug 24 06:13 PM
SING GEORGE L	Director	Aug 20	Sale	616.91	21,000	12,955,042	104,415	Aug 24 06:13 PM
VAGELOS P ROY	Director	Aug 11	Sale	602.94	33,460	20,174,355	50,192	Aug 13 04:02 PM
Landry Robert E	EVP Finance CFO	Aug 04	Sale	654.46	696	455,504	23,973	Aug 05 05:07 PM
RYAN ARTHUR F	Director	Aug 03	Sale	641.93	100	64,193	28,543	Aug 05 05:09 PM
Landry Robert E	EVP Finance CFO	Jul 21	Sale	647.58	391	253,204	24,669	Jul 22 04:30 PM
Fenimore Christopher R.	VP Controller	Jul 21	Sale	642.04	3,709	2,381,317	17,501	Jul 22 04:31 PM
Fenimore Christopher R.	VP Controller	Jul 20	Option Exercise	156.01	12,224	1,907,015	25,277	Jul 22 04:31 PM
Landry Robert E	EVP Finance CFO	Jul 20	Option Exercise	491.43	8,500	4,177,160	29,671	Jul 22 04:30 PM
Landry Robert E	EVP Finance CFO	Jul 14	Sale	640.50	579	370,850	23,973	Jul 14 04:17 PM
MURPHY ANDREW J	EVP Research	Jul 14	Sale	633.48	2,380	1,507,677	41,951	Jul 15 04:51 PM
MURPHY ANDREW J	EVP Research	Jul 14	Sale	623.89	3,929	2,451,277	44,331	Jul 15 04:51 PM
MURPHY ANDREW J	EVP Research	Jul 13	Option Exercise	30.63	13,000	398,190	54,951	Jul 15 04:51 PM
MURPHY ANDREW J	EVP Research	Jul 13	Sale	628.50	8,000	5,028,022	41,951	Jul 15 04:51 PM
Landry Robert E	EVP Finance CFO	Jul 09	Option Exercise	399.66	3,000	1,198,980	26,973	Jul 13 04:28 PM
Landry Robert E	EVP Finance CFO	Jul 08	Sale	639.66	1,160	742,011	23,973	Jul 09 04:29 PM
SING GEORGE L	Director	Jul 07	Option Exercise	33.42	7,500	250,650	122,915	Jul 08 04:16 PM
Zoghbi Huda Y	Director	Jul 07	Option Exercise	391.92	1,706	668,616	2,349	Jul 08 04:14 PM
Landry Robert E	EVP Finance CFO	Jul 07	Option Exercise	524.47	12,500	6,555,850	33,973	Jul 09 04:29 PM
SING GEORGE L	Director	Jul 07	Sale	650.16	3,000	1,950,474	400	Jul 08 04:16 PM
SING GEORGE L	Director	Jul 07	Sale	650.00	7,500	4,875,000	115,415	Jul 08 04:16 PM
Zoghbi Huda Y	Director	Jul 07	Sale	650.00	1,706	1,108,900	643	Jul 08 04:14 PM
BROWN MICHAEL S	Director	Jul 01	Option Exercise	413.33	3,613	1,493,361	4,256	Jul 02 04:02 PM
BROWN MICHAEL S	Director	Jul 01	Sale	607.62	3,613	2,195,342	643	Jul 02 04:02 PM
RYAN ARTHUR F	Director	Jul 01	Sale	609.70	100	60,970	28,643	Jul 02 04:01 PM
SING GEORGE L	Director	Jun 29	Sale	608.91	3,000	1,826,721	1,400	Jun 29 04:08 PM
Landry Robert E	EVP Finance CFO	Jun 29	Sale	612.57	400	245,029	23,973	Jun 30 04:02 PM
Landry Robert E	EVP Finance CFO	Jun 23	Sale	631.27	512	323,212	24,373	Jun 24 04:03 PM
Landry Robert E	EVP Finance CFO	Jun 22	Option Exercise	555.67	8,900	4,945,463	33,273	Jun 24 04:03 PM
Bassler Bonnie L	Director	Jun 19	Option Exercise	391.92	2,559	1,002,923	3,202	Jun 22 04:18 PM
Bassler Bonnie L	Director	Jun 19	Sale	630.02	2,559	1,612,211	643	Jun 22 04:18 PM
Fenimore Christopher R.	VP Controller	Jun 16	Sale	590.89	3,556	2,101,215	15,277	Jun 17 04:02 PM
Fenimore Christopher R.	VP Controller	Jun 15	Option Exercise	47.07	9,406	442,742	20,323	Jun 17 04:02 PM
Zoghbi Huda Y	Director	Jun 11	Option Exercise	391.92	1,706	668,616	2,349	Jun 12 04:03 PM
Zoghbi Huda Y	Director	Jun 11	Sale	625.00	1,706	1,066,250	643	Jun 12 04:03 PM
Landry Robert E	EVP Finance CFO	Jun 11	Sale	612.08	988	604,731	24,373	Jun 12 04:01 PM
Landry Robert E	EVP Finance CFO	Jun 10	Option Exercise	272.70	3,500	954,450	27,873	Jun 12 04:01 PM
Zoghbi Huda Y	Director	Jun 10	Option Exercise	391.92	1,706	668,616	2,349	Jun 12 04:03 PM
Zoghbi Huda Y	Director	Jun 10	Sale	610.24	1,706	1,041,068	643	Jun 12 04:03 PM
Landry Robert E	EVP Finance CFO	Jun 09	Sale	608.01	4,271	2,596,792	24,373	Jun 10 04:04 PM
GOLDSTEIN JOSEPH L	Director	Jun 08	Option Exercise	413.33	10,838	4,479,671	17,481	Jun 09 04:05 PM
Landry Robert E	EVP Finance CFO	Jun 08	Option Exercise	272.70	15,500	4,226,850	29,860	Jun 10 04:04 PM
GOLDSTEIN JOSEPH L	Director	Jun 08	Sale	592.95	10,838	6,426,362	6,643	Jun 09 04:05 PM
Bassler Bonnie L	Director	Jun 05	Option Exercise	391.92	2,559	1,002,923	3,202	Jun 05 04:15 PM
Bassler Bonnie L	Director	Jun 05	Sale	600.00	2,559	1,535,400	643	Jun 05 04:15 PM
RYAN ARTHUR F	Director	Jun 01	Sale	603.23	100	60,323	28,743	Jun 02 04:04 PM
SING GEORGE L	Director	May 29	Sale	596.51	1,000	596,510	2,400	Jun 01 04:08 PM
GOLDSTEIN JOSEPH L	Director	May 28	Sale	578.94	1,000	578,940	6,643	Jun 01 04:02 PM
SING GEORGE L	Director	May 28	Sale	579.00	1,000	579,000	2,900	Jun 01 04:08 PM
VAGELOS P ROY	Chairman of the Board	May 21	Sale	577.49	783	452,178	307,749	May 22 06:21 PM
VAGELOS P ROY	Chairman of the Board	May 21	Sale	564.37	148,811	83,984,786	308,532	May 22 06:21 PM
VAGELOS P ROY	Chairman of the Board	May 20	Option Exercise	30.63	312,500	9,571,875	497,063	May 22 06:21 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	May 15	Sale	572.00	8,380	4,793,360	14,438	May 15 04:03 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	May 14	Option Exercise	59.20	18,311	1,084,011	32,749	May 15 04:03 PM
SING GEORGE L	Director	May 13	Option Exercise	33.42	5,000	167,100	120,415	May 13 09:00 PM
SING GEORGE L	Director	May 13	Sale	580.00	5,000	2,900,000	115,415	May 13 09:00 PM
SCHLEIFER LEONARD S	President & CEO	May 12	Sale	569.22	150,922	85,908,042	474,499	May 13 09:01 PM
SCHLEIFER LEONARD S	President & CEO	May 11	Option Exercise	30.63	312,500	9,571,875	722,368	May 13 09:01 PM
SING GEORGE L	Director	May 11	Sale	575.00	850	488,750	2,150	May 13 09:00 PM
STAHL NEIL	EVP Research and Development	May 11	Sale	569.52	5,305	3,021,289	11,380	May 11 04:39 PM
STAHL NEIL	EVP Research and Development	May 08	Option Exercise	52.03	12,500	650,375	23,880	May 11 04:39 PM
Zoghbi Huda Y	Director	May 07	Option Exercise	391.92	5,118	2,005,847	5,761	May 08 04:03 PM
Van Plew Daniel P	EVP & General Mgr Industrial O	May 07	Sale	564.32	39,583	22,337,306	28,251	May 08 04:04 PM
Zoghbi Huda Y	Director	May 07	Sale	566.52	5,118	2,899,461	643	May 08 04:03 PM
BROWN MICHAEL S	Director	May 07	Sale	562.00	1,809	1,016,658	643	May 07 04:14 PM
BROWN MICHAEL S	Director	May 06	Option Exercise	371.98	5,470	2,034,739	5,863	May 07 04:14 PM
Tessier-Lavigne Marc	Director	May 06	Option Exercise	177.82	15,000	2,667,300	16,830	May 08 04:03 PM
RYAN ARTHUR F	Director	May 06	Option Exercise	373.67	50,124	18,729,670	78,967	May 07 06:22 PM
Van Plew Daniel P	EVP & General Mgr Industrial O	May 06	Option Exercise	52.03	85,579	4,452,675	96,051	May 08 04:04 PM
Tessier-Lavigne Marc	Director	May 06	Sale	563.97	15,000	8,459,496	1,830	May 08 04:03 PM
GOLDSTEIN JOSEPH L	Director	May 06	Sale	560.00	2,000	1,120,000	7,643	May 06 04:19 PM
RYAN ARTHUR F	Director	May 06	Sale	550.88	50,124	27,612,509	28,843	May 07 06:22 PM
RYAN ARTHUR F	Director	May 01	Sale	520.37	100	52,037	28,843	May 04 04:02 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Apr 20	Sale	565.48	3,522	1,991,611	16,216	Apr 20 07:26 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Apr 20	Sale	570.30	1,778	1,013,985	14,438	Apr 20 07:27 PM
Landry Robert E	EVP Finance CFO	Apr 20	Sale	566.94	3,250	1,842,539	24,373	Apr 20 07:29 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Apr 17	Option Exercise	59.20	11,622	688,022	22,458	Apr 20 07:26 PM
Landry Robert E	EVP Finance CFO	Apr 17	Option Exercise	272.70	12,500	3,408,750	36,873	Apr 20 07:29 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience